The instruction for medical use
of N25 Kurantil® medicine
the Trade name
of Kurantil® of N25
the International unlicensed
name Dipiridamolum Dosage Form
of the Tablet, film coated 25 mg
One tablet contains
active agent – Dipiridamolum of 25 mg,
structure of a kernel: corn starch, lactoses monohydrate, sodium of starch glikolit (type A), gelatin, silicon dioxide colloidal anhydrous, magnesium stearate,
structure of a cover: a gipromelloza, talc, a macrogoal 6000, the titan dioxide (E 171), quinolinic yellow (E 104), an emulsion of a simetikon
Yellow round ploskotsilindrichesky tablets, the film coated, having almost plane-parallel surfaces
Anticoagulants. Inhibitors of aggregation of thrombocytes, excepting heparin. Dipiridamolum.
The ATX B01AC07 code
Pharmacokinetics Later properties of oral introduction Dipiridamolum is quickly soaked up in digestive tract (mostly — in a stomach and partially — in a small intestine).
After oral administration the maximum concentration of Dipiridamolum in plasma is reached in 1 hour. Dipiridamolum almost completely contacts proteins of plasma. It collects in heart and in erythrocytes, and is metabolized — in a liver by linking with glucuronic acid. Elimination half-life makes 20–30 minutes. Dipiridamolum with bile in the form of a monoglucuronide is removed.
of Kurantil® N 25 has the braking impact on aggregation of thrombocytes and improves microcirculation. Drug possesses soft vasodilating action.
The mechanism on which Dipiridamolum renders the inhibiting effect on aggregation of thrombocytes can be caused by inhibition of absorption of the adenosine (which is inhibitor of reactivity of thrombocytes), inhibition of phosphodiesterase of thrombocytes or stimulation of release of prostacyclin (PGI2).
Dipiridamolum slows down absorption of adenosine endothelial cells, erythrocytes and thrombocytes. So, after Dipiridamolum use, observed the increased concentration of adenosine in blood, the aggregation of thrombocytes provided to them and a thrombogenesis decreased. Besides, the vazodilatiruyushchy effect of adenosine amplified.
Enzyme phosphodiesterase destroys the cyclic adenosinemonophosphate inhibiting aggregation (ts-AMF) in thrombocytes. Dipiridamolum inhibits phosphodiesterase of thrombocytes, leading to accumulation in them ts-AMF.
– treatment and prevention of disturbances of cerebral circulation on ischemic type
– prevention of arterial and venous thromboses and also their complications
– prevention of a thrombembolia after operation of prosthetics of valves of heart
the Route of administration and doses
If is not offered other, then the following instructions on a dosage work:
For reduction of aggregation of thrombocytes the reception of 75-225 mg Dipiridamolums/day (3-9 tablets Kurantila® N 25, film coated) distributed on several receptions is recommended. In hard cases the dose can be increased up to 600 mg Dipiridamolums/day.
For treatment and prevention of disturbances of cerebral circulation reception of 3 tablets Kurantila® N 25 3-6 of times a day (225–450 mg of Dipiridamolum) is recommended. The maximum dose of Dipiridamolum should not exceed 450 mg/days (corresponds to 18 tablets Kurantila® N 25, film coated).
Therapy should be begun with gradually accruing doses, and a tablet, film coated, to accept on an empty stomach, without getting to the core and without breaking them and also washing down with liquid.
Duration of treatment and a dose should be established depending on individual requirement and shipping.
Курантил® N 25 is suitable for performing long-term treatment.
the Side reactions arising during use of Kurantil® N 25 in medical doses, usually weak and passing
– vomiting, a diarrhea, nausea
– dizziness, a headache (including a headache of vascular origin) and muscle pains (usually these side effects disappear at more prolonged use of Kurantila® N 25)
– hypersensitivity reactions as quickly passing skin rash and a small tortoiseshell
– increase in tendency to bleedings in time or after surgical intervention
– exacerbation of coronary heart disease
– a myocardial infarction
Frequency is unknown
– pains in epigastriums
– heartbeat, tachycardia, bradycardia, inflows of blood to the person, a syndrome of coronary burglarizing (when using doses more than 225 mg/days).
– thrombocytopenia, change of functional properties of thrombocytes, increase in tendency to bleedings
– weakness, feeling of congestion of an ear, noise in the head, arthritis, rhinitis
– as a result of possible vasodilating action, Курантил®N 25 in high doses can cause hypotension, feeling of heat and tachycardia, especially at the patients taking other vascular drugs
– was shown that Dipiridamolum can be a part of stones of a gall bladder.
– recently postponed myocardial infarction
– unstable stenocardia
– the widespread stenosing atherosclerosis of coronary arteries
– a subaortal stenosis
– dekompensirovanny heart failure
– arterial hypotension, collapse
– heavy disturbances of a warm rhythm
– hemorrhagic diathesis
– diseases with tendency to bleedings (a peptic ulcer of a stomach and a 12-perstny gut, etc.)
– hypersensitivity to any of drug components
– children’s and teenage age up to 18 years
– the lactation period
Ksantinovy derivatives (contain, for example, in coffee and tea) can weaken vasodilating action of Kurantila® N 25.
It is necessary to consider that at simultaneous use of Kurantila® N 25 and anticoagulants or acetylsalicylic acid or klopidogrelya antitrombotichesky properties of the last amplify. If Kurantil® N 25 is applied along with acetylsalicylic acid or anticoagulants, then it is necessary to consider information on risk and incompatibility of these medicines.
Dipiridamolum can strengthen effect of hypotensive drugs.
Dipiridamolum can weaken cholinergic properties of inhibitors of cholinesterase.
Use of antacids can reduce efficiency of Kurantila® N 25.
Β-laktamny antibiotics, tetracycline and chloramphenicol enhance effect of Dipiridamolum.
Dipiridamolum increases concentration of adenosine in blood plasma and strengthens its vasodilating action. If there is an imperative need in combined use with Dipiridamolum, the dosage of adenosine is subject to correction. Dipiridamolum can also suppress absorption of a fludarabin and reduce its efficiency.
Dipiridamolum can cause insignificant increase in absorption of digoxin.
indications Pregnancy Safety of use Kurantil® N 25 at pregnancy it is not established in this regard drug it is not necessary to use during pregnancy, especially in the first trimester, except for cases when the expected advantage for the patient more possible risk for a fruit
of Kurantil® of N25 contains lactose therefore it is not recommended to patients with rare hereditary intolerance of a galactose, deficiency of lactase or a sprue of glucose galactose.
Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
Even at appropriate use of Kurantil® N 25 can affect ability to driving of vehicles and service of cars as reaction change can be caused by falling of blood pressure indirectly.
Symptoms: general vazodilatation which is followed by hypotonia, complaints characteristic of stenocardia, tachycardia, feeling of heat, face reddening, weakness and dizziness, concern.
Treatment: symptomatic therapy in oral intoxication:
– removal of toxin (gastric lavage, calling of vomiting)
– measures for absorption reduction.
Dilatiruyushchy action of Kurantila® N 25 can be stopped slow intravenous administration of Aminophyllinum (50-100 mg during 60 sec.). If after that the complaints connected with stenocardia remain, then perhaps use of nitroglycerine is sublingual.
The form of release and packing
On 120 tablets place in bottles of colourless glass with a capacity of 30 ml with polyethylene traffic jams.
On 1 bottle together with the instruction for medical use in the state and Russian languages put in a pack from cardboard.
To Store storage conditions at a temperature not above 25 °C.
To store out of children’s reach!
not to use a period of storage after an expiration date.
According to the prescription
Proizvoditel Berlin-Hemi AG (Menarini Group) Gliniker Weg 125 D-12489 Berlin, Germany
the Owner of the registration certificate
of Berlin-Hemi AG (Menarini Group), Germany
the Menarini Organization packer – Von Haden GmbH, Germany
the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers concerning quality of products (goods): Representative office of JSC Berlin-Hemi AG in RKTEL.: +7 727 2446183, 2446184, 2446185 Fax: +7 727 2446180 E-mail address:
To Develop Kazakhstan@berlin-chemie.com